Amgen
 
4Q Revenues: $5.5 billion (+4%)

4Q Earnings: $1.8 billion (+39%)

FY Revenues: $6.9 billion (+35%)

FY Earnings: $21.7 billion (+8%)

Comments: Product sales increased 3% in the quarter, with growth driven by Enbrel (+8% to $1.4 billion), Sensipar(+21% to $384 million), Prolia (+21% to $380 million), Kyprolis (+63% to $148 million), and XGEVA (+10% to $356 million). Neulasta sales were down 2% to $1.2 billion, Neupogen sales were down 4% to $263 million, and Epogen sales were down 37% to $342 million, due to competition.